Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
On October 16, 2018, the U.S. Food and Drug Administration (FDA) approved talazoparib for patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. Patients must be selected for therapy based on an FDA-approved companion diagnostic for talazoparib.
Talazoparib was associated with superior efficacy, favorable patient-reported outcomes (PROs), and lower health resource utilization (HRU) rate versus chemotherapy in advanced Breast Cancer / Mammacarcinoma (BRCA m). Toxicities were manageable with talazoparib dose modification and supportive care.
see also:
[PARPs (Poly(ADP-Ribose) Polymerases) Inhibitors & Breast Cancer / Mammac…